Related references
Note: Only part of the references are listed.Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
Bodvael Pennarun et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL
Bodvael Pennarun et al.
ANALYTICAL CELLULAR PATHOLOGY (2010)
Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
Zhaoyu Jin et al.
CELL (2009)
Targeting TRAIL death receptors
C. N. A. M. Oldenhuis et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Insulin and insulin-like growth factor signalling in neoplasia
Michael Pollak
NATURE REVIEWS CANCER (2008)
Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 is not necessary for but contributes to sensitization of primary human glioma cells to TRAIL
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor - Related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2
Mitchell R. Smith et al.
CLINICAL CANCER RESEARCH (2007)
Life and death in peripheral T cells
Peter H. Krammer et al.
NATURE REVIEWS IMMUNOLOGY (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells
Xiangguo Liu et al.
CANCER RESEARCH (2007)
Analysis of CD95 threshold signaling - Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling
Inna N. Lavrik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L)
Wenhua Li et al.
CANCER RESEARCH (2007)
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2
Delphine Merino et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
S. Fulda et al.
ONCOGENE (2006)
The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells
Albert F. Kabore et al.
APOPTOSIS (2006)
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor
Almer M. van der Sloot et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis
BMT Hougardy et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
GV Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation
HB Zhu et al.
CANCER BIOLOGY & THERAPY (2005)
Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein
T Yoshida et al.
CANCER RESEARCH (2005)
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
L Pukac et al.
BRITISH JOURNAL OF CANCER (2005)
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution
RF Kelley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells
Q He et al.
ONCOGENE (2004)
Regulation of apoptosis proteins in cancer cells by ubiquitin
HG Zhang et al.
ONCOGENE (2004)
Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms
S Shankar et al.
PROSTATE (2004)
Targeting death receptors in cancer with Apo2/TRAIL
SK Kelley et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation
LR Thomas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma
MS Merchant et al.
CANCER RESEARCH (2004)
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors
B Zheng et al.
CLINICAL CANCER RESEARCH (2004)
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines
CMM van Geelen et al.
BRITISH JOURNAL OF CANCER (2003)
TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis
K Ichikawa et al.
JOURNAL OF IMMUNOLOGY (2003)
TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes:: Differential contribution of TRAIL receptors 1 and 2
M Leverkus et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8.
FC Kischkel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
K Ichikawa et al.
NATURE MEDICINE (2001)
Interferon-γ sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism
N Varela et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
A Chuntharapai et al.
JOURNAL OF IMMUNOLOGY (2001)
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
JL Bodmer et al.
NATURE CELL BIOLOGY (2000)
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
AM Chinnaiyan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
